Videos

PSMA Clinical Trials Offer ‘Another Tool in the Toolbox’ for Prostate Cancer

October 6th 2022

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about PSMA, what it is and how it is advancing the prostate cancer landscape.

‘Planning Your Next Shot’ In the Prostate Cancer Continuum With Patient-Physician Communication

October 6th 2022

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about the importance of patient-physician communication in prostate cancer.

Although Patients With Prostate Cancer Have Differing Support Group Needs, Advocoate Says ‘Don’t Stop Looking’

October 6th 2022

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about seeking support after a prostate cancer diagnosis.

Lung Cancer Survivor Urges Others to Participate in Research, Says it ‘Will Make a Difference in the Future’ of Others

October 5th 2022

A breast cancer research nurse and lung cancer survivor stresses the importance of participating in clinical trials that are investigating the latest treatments.

Lung Cancer Space Must ‘Maximize’ the People Who Benefit From Advancements

October 3rd 2022

Lung cancer advocates and clinicians must ”fight” for every patient with the disease and ensure that the most amount of people can benefit from advancements in the field, according to an advocate.

Living Well Beyond Bladder Cancer With Support

September 29th 2022

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about support available for patients and caregivers following a bladder cancer diagnosis.

Expert Discusses Effects of a Bladder Cancer Diagnosis on Caregivers and the Support Available to Them

September 29th 2022

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about the role of the caregiver in bladder cancer and how they can also seek support to aid them.

Patients Can Help Move the Needle Forward in Bladder Cancer Clinical Trials With Participation

September 29th 2022

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how patients can find clinical trials they may be eligible for.

Having Open and Honest Conversations With Oncologists Aids in Patient-Physician Communication in Bladder Cancer

September 29th 2022

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about letting physicians know about patient preferences to improve communication and select the right treatment option.

Combining Old and New Therapies in Advanced Bladder Cancer Shows Promise for the Future

September 29th 2022

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how currently available agents are being investigated in combination with one another.

Uveal and Skin Melanoma Share a Common Name, But That’s The Only Similarity, Says Expert

September 21st 2022

Melanoma of the skin has been shown to be greatly associated with exposure to sunlight, whereas uveal melanoma — commonly known as cancer of the eye — is not.

Antibody Drug Conjugates ‘Make Chemotherapy Targeted’ for Patients With Cancer

September 19th 2022

An expert explains how antibody drug conjugates work to treat cancer.

Educated Patient Webinar: Deep Dive into TIL Cell Therapy for Those Living with Cancer

September 19th 2022

Advice for Patients Living with Metastatic Uveal Melanoma

September 2nd 2022

Sunandana Chandra, MD, MS, closes by sharing advice for patients with metastatic uveal melanoma.

Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

September 2nd 2022

An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.

Never Ever Ever Give Up

August 29th 2022

Expert Breaks Down Immunotherapy Options in Kidney Cancer

August 25th 2022

In recent years, immunotherapy’s usage has expanded for the treatment of patients with kidney cancer.

An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

August 24th 2022

Dr Sunandana Chandra highlights her personal experience in prescribing tebentafusp and other therapies for mUM, and discusses the educational resources and advocacy organizations that she encourages patients to look into to help make an informed decision about their treatment regimens.

Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

August 24th 2022

An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.

Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

August 18th 2022

Sunandana Chandra, MD, MS, discusses safety and efficacy data from the IMCgp100-202 trial on tebentafusp, and comments on the clinical implications of these data.

Historic and Current Treatment Options for mUM

August 18th 2022

An expert provides an overview of the historical and currently available treatment options in metastatic uveal melanoma (mUM), including the bispecific T-cell receptor immunotherapy tebentafusp (“teh-BEN-tah-fuhsp”).

Patients With Cancer Should Speak Up About Mental Health Struggles if They Don’t Feel Heard, Expert Says

August 15th 2022

A psychiatrist advises patients with cancer to speak up about their mental health concerns during cancer treatment, as there are tools that can guide best next steps.

Support and Advice for Patients with mCRPC and Their Caregivers

August 11th 2022

Joseph Wood and his caregiver, Deborah Wood, provide advice for patients and caregivers with prostate cancer who may be in similar situations, and comment on the support they have received from their family and community.

Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

August 10th 2022

Dr Sunandana Chandra describes the typical symptoms that patients with uveal melanoma experience, the prevalent asymptomatic patient population, and how optometrists and ophthalmologists may be involved in the diagnostic process.

How Uveal Melanoma Differs from Cutaneous Melanoma

August 10th 2022

Sunandana Chandra, MD, MS, explains how uveal melanoma is different from cutaneous melanoma, including prevalence, molecular mutations, and survival prognosis after metastasis.

Expert Advises Patients With Breast Cancer They Can Forgo Certain Supplements

August 10th 2022

Many patients with breast cancer ask about the benefits of the supplement sulforaphane, but a naturopathic doctor advises patients that it is best to get the compound from food rather than supplements.

Follow-up and Side Effects in Patients Treated with Lutetium 177-PSMA 167

August 8th 2022

Joseph Wood and his wife and caregiver, Deborah, share their concerns and questions about radioligand therapy and how the COVID-19 pandemic has impacted their treatment experience.

Genetic Testing May 'Open New Doors for New Treatments' in Prostate Cancer

August 4th 2022

In this video, an expert discusses which men with prostate cancer are eligible for genetic testing, and what patients can do if they are not eligible but want to undergo testing anyway.

Outcomes Are Best When Patients With Cancer Are as Aware of Their Disease as Their Provider, Expert Says

August 2nd 2022

Patients with cancer are encouraged to learn more about their disease from evidenced-based sources and not “Dr. Google.”

Clinical Considerations Related to Lutetium 177– PSMA-617 Treatment in mCRPC

August 2nd 2022

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer (mCRPC).